ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 7.350-7.650 for the period, compared to the consensus earnings per share estimate of 6.370. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ICUI. Raymond James Financial reduced their price objective on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research report on Friday, August 8th. Piper Sandler raised their target price on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. KeyCorp cut their target price on ICU Medical from $191.00 to $173.00 and set an “overweight” rating for the company in a research note on Tuesday, October 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.50.

ICU Medical Trading Up 1.8%

NASDAQ ICUI traded up $2.29 on Thursday, hitting $129.67. 429,593 shares of the stock were exchanged, compared to its average volume of 267,995. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The stock has a fifty day moving average price of $123.82 and a two-hundred day moving average price of $128.19. The firm has a market capitalization of $3.20 billion, a P/E ratio of -85.31 and a beta of 0.83. ICU Medical has a 52-week low of $107.00 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping the consensus estimate of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 earnings per share. Research analysts forecast that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain bought 21,929 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the transaction, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Greenberg acquired 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, with a total value of $151,704.00. Following the completion of the acquisition, the director directly owned 7,960 shares of the company’s stock, valued at $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in shares of ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after acquiring an additional 101 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of ICU Medical by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock valued at $325,000 after acquiring an additional 107 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after acquiring an additional 229 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of ICU Medical by 1.1% in the second quarter. California State Teachers Retirement System now owns 21,508 shares of the medical instruments supplier’s stock valued at $2,842,000 after acquiring an additional 239 shares in the last quarter. Finally, Occudo Quantitative Strategies LP raised its holdings in shares of ICU Medical by 4.6% in the second quarter. Occudo Quantitative Strategies LP now owns 5,878 shares of the medical instruments supplier’s stock valued at $777,000 after acquiring an additional 261 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.